The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease

BACKGROUND: The non-interventional PROPER study generated real-world evidence on clinical outcomes following transition in routine practice from reference adalimumab to the EMA-approved SB5 biosimilar adalimumab in patients with immune-mediated inflammatory disease. METHODS: Adults with rheumatoid a...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller-Ladner, Ulf, Dignass, Axel, Gaffney, Karl, Jadon, Deepak, Matucci-Cerinic, Marco, Lobaton, Triana, Carron, Philippe, Gisbert, Javier P., Pande, Ira, Utzinger, Maximilian, Addison, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581927/
https://www.ncbi.nlm.nih.gov/pubmed/37632666
http://dx.doi.org/10.1007/s40259-023-00616-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581927/
https://www.ncbi.nlm.nih.gov/pubmed/37632666
http://dx.doi.org/10.1007/s40259-023-00616-3

Ejemplares similares